Holen Sie sich die Stockscreener-App
7.32
1.88%
-0.14
Handel nachbörslich:
7.30
-0.02
-0.27%
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget
Kush Parmar Sells 92,444 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares - MarketBeat
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan
Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics, Inc. 2026: Revenue $898K, EPS ($1.01) — 10-Q Summary - TradingView
Entrada Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times
Entrada Therapeutics reports Q2 2026 results: $223.0M cash; Q2 net loss $42.8M - TradingView
Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline - Stock Titan
Entrada Therapeutics director Kush Parmar sells $807,027 in shares By Investing.com - Investing.com India
5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com - Investing.com India
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
5am Ventures V sells $807,027 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics director Kush Parmar sells $807,027 in shares - Investing.com
Ventures L.P. 5Am Sells 114,756 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - marketbeat.com
Form 4 Entrada Therapeutics Inc For: 4 August By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Entrada Therapeutics Insider Sold Shares Worth $807,027, According to a Recent SEC Filing - marketscreener.com
Entrada Therapeutics (TRDA) holder sells shares, still reports 1.09M stake - stocktitan.net
Liquidity Mapping Around (TRDA) Price Events - Stock Traders Daily
Entrada Therapeutics Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Form 144 ENTRADA THERAPEUTICS For: 30 July By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. SEC Filing (Jul 30, 2026) - Stock Titan
Entrada Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entrada Therapeutics Inc (TRDA) Cash Flow - TradingKey
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entrada Therapeutics (TRDA) Climbs 5.47%: Support and Resistance in FocusSmart Money Flow Stocks - dars.gov.et
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Balance Sheet - TradingKey
Entrada Therapeutics Inc|Price:5.850|Chg%:-0.200 - TradingKey
Entrada Therapeutics (TRDA) Slides 3.33% as Stock Tests Key Support LevelsHigh Beta Stocks - dars.gov.et
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Mild Stock UptickBanking Earnings Report - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Entrada Therapeutics (TRDA) Gains 4.6% as Biotech Stock Tests Key Resistance Near $7.47Bullish Sentiment - dars.gov.et
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):